India on Tuesday recorded the lowest number of cases in five months – 26,567 in the past 24 hours, government data shows. The daily case count fell amid preparations to start vaccinating high-risk groups.
With new cases, the general coronavirus
the tally has crossed 97 lakh-mark- 97,03,770, while the death toll rose to 1,40,958 with 385 new deaths, data updated by the ministry at 8 am showed. The number of people who have recovered from the disease increased to 91.78,946, raising the national recovery rate to 94.59%, while the COVID-19 the fatality rate was 1.45%.
The number of cases is the lowest since July 10, the third indicator to reach July levels after active cases and daily deaths, which stood at 385 for the day. On Sunday, daily Covid-related deaths also fell below the 400 mark after five months, according to the Health Ministry.
From india COVID-19 the account had crossed the 20 lakh mark on August 7, 30 lakh on August 23, and 40 lakh on September 5. It had gone from 50 lakh on September 16, 60 lakh on September 28, 70 lakh on October 11, crossed 80 lakh on October 29, and exceeded 90 lakh on November 20.
According to the Indian Council of Medical Research, 14,88,14,055 samples have been analyzed as of December 7, and 10,26,399 samples have been analyzed.
Meanwhile, on Monday, Hyderabad-based pharmaceutical company Bharat Biotech applied to the central drug regulator for an emergency use authorization for its COVID-19 Covaxin vaccine. It is being developed indigenously by Bharat Biotech in collaboration with the Indian Council for Medical Research (ICMR).
The company is currently conducting phase 3 clinical trials of its vaccine in around 25 locations, including Delhi, Mumbai, Patna and Lucknow. However, when requesting the phase 3 trial, the company had stated that the vaccine was well tolerated in all dose groups and no serious adverse effects had been reported.
A committee of experts from the Central Medicines Standards Control Organization (CDSCO) will meet on Wednesday to review applications from Pfizer, Serum Institute of India and Bharat Biotech seeking emergency use authorization for their COVID-19 vaccine candidates.
After Prime Minister Narendra Modi expressed his hope on December 4 that COVID-19 The vaccine could be ready in a few weeks, the Indian branch of the US pharmaceutical giant Pfizer had applied for approval for its vaccine from the central drug regulator, after the company obtained such authorization in the UK and Bahrain.
.
